MXPA06001647A - 6-(2, 2, 2-trifluoroetilamino) -7-cloro-2, 3, 4, 5-tetrahidro- 1h-benzo[d] azepina como un agonista del receptor 5-ht2c. - Google Patents

6-(2, 2, 2-trifluoroetilamino) -7-cloro-2, 3, 4, 5-tetrahidro- 1h-benzo[d] azepina como un agonista del receptor 5-ht2c.

Info

Publication number
MXPA06001647A
MXPA06001647A MXPA06001647A MXPA06001647A MXPA06001647A MX PA06001647 A MXPA06001647 A MX PA06001647A MX PA06001647 A MXPA06001647 A MX PA06001647A MX PA06001647 A MXPA06001647 A MX PA06001647A MX PA06001647 A MXPA06001647 A MX PA06001647A
Authority
MX
Mexico
Prior art keywords
ht2c
trifluoroethylamino
azepine
benzo
tetrahydro
Prior art date
Application number
MXPA06001647A
Other languages
English (en)
Inventor
Michael John Rodriguez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA06001647A publication Critical patent/MXPA06001647A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona una 7-cloro -6-(2, 2, 2-trifluoroetilamino) -2, 3, 4, 5-tetrahidro- 1H-benzo[d] azepina de la Formula I: (ver formula (I)) o una sal farmaceuticamente aceptable de la misma, y su uso como un agonista selectivo del 5-HT2C para el tratamiento de desordenes asociados con el 5-HT2C incluyendo obesidad, desorden obsesivo/compulsivo, ansiedad y depresion.
MXPA06001647A 2003-08-11 2004-07-30 6-(2, 2, 2-trifluoroetilamino) -7-cloro-2, 3, 4, 5-tetrahidro- 1h-benzo[d] azepina como un agonista del receptor 5-ht2c. MXPA06001647A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49420803P 2003-08-11 2003-08-11
PCT/US2004/022299 WO2005019180A1 (en) 2003-08-11 2004-07-30 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A 5-HT2c RECEPTOR AGONIST

Publications (1)

Publication Number Publication Date
MXPA06001647A true MXPA06001647A (es) 2006-04-28

Family

ID=34215860

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06001647A MXPA06001647A (es) 2003-08-11 2004-07-30 6-(2, 2, 2-trifluoroetilamino) -7-cloro-2, 3, 4, 5-tetrahidro- 1h-benzo[d] azepina como un agonista del receptor 5-ht2c.

Country Status (11)

Country Link
US (1) US20060264418A1 (es)
EP (1) EP1656352A1 (es)
JP (1) JP2007502272A (es)
CN (1) CN1832926A (es)
AR (1) AR045229A1 (es)
AU (1) AU2004267027A1 (es)
BR (1) BRPI0413342A (es)
CA (1) CA2532020A1 (es)
MX (1) MXPA06001647A (es)
TW (1) TW200510324A (es)
WO (1) WO2005019180A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
DE602006008323D1 (de) * 2005-09-01 2009-09-17 Lilly Co Eli 6-substituierte- 2,3,4,5-tetrahydro-1h-benzoädüazepine als 5-ht2c-rezeptoragonisten
SI1926712T1 (sl) * 2005-09-01 2010-01-29 Lilly Co Eli 6-substituirani 2,3.4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja
WO2007028083A2 (en) 2005-09-01 2007-03-08 Eli Lilly And Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
CA2619450C (en) * 2005-09-01 2013-10-22 Eli Lilly And Company 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
WO2007140213A1 (en) 2006-05-26 2007-12-06 Forest Laboratories Holdings Limited Pyridoazepine derivatives
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
CN102015591B (zh) 2008-03-04 2014-01-29 艾尼纳制药公司 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2，3，4，5-四氢-1h-3-苯并氮杂卓相关的中间体的方法
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
WO2011153206A1 (en) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
KR20140091458A (ko) 2010-09-01 2014-07-21 아레나 파마슈티칼스, 인크. 신장 손상을 갖는 개체에 대한 로카세린의 투여
KR20130101524A (ko) 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
AU2011296003B2 (en) 2010-09-01 2015-11-12 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-HT2C agonist useful for weight management
CN103189359A (zh) * 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的光学活性酸盐
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CN103189358A (zh) * 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的快速溶解剂型
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103145619A (zh) * 2012-06-15 2013-06-12 史慎德 7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
CA2886875A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH498122A (de) * 1968-02-09 1970-10-31 Geigy Ag J R Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates
FR2358151A1 (fr) * 1976-03-31 1978-02-10 Roussel Uclaf Nouvelles benzazepines et leurs sels, procede de preparation et application a titre de medicaments
KR940701258A (ko) * 1991-06-21 1994-05-28 피터 죤 기딩즈 문맥압 항진증 및 편두통의 치료를 위한 테트라하이드로벤즈아제핀 유도체의 용도
JPWO2002074746A1 (ja) * 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
WO2003045940A2 (en) * 2001-11-28 2003-06-05 Pharmacia & Upjohn Company Benzazepine derivatives and their use as 5-ht ligands
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
GB0212399D0 (en) * 2002-05-29 2002-07-10 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
US20060264418A1 (en) 2006-11-23
EP1656352A1 (en) 2006-05-17
WO2005019180A1 (en) 2005-03-03
AR045229A1 (es) 2005-10-19
AU2004267027A1 (en) 2005-03-03
CN1832926A (zh) 2006-09-13
JP2007502272A (ja) 2007-02-08
BRPI0413342A (pt) 2006-10-10
CA2532020A1 (en) 2005-03-03
TW200510324A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
MXPA06001647A (es) 6-(2, 2, 2-trifluoroetilamino) -7-cloro-2, 3, 4, 5-tetrahidro- 1h-benzo[d] azepina como un agonista del receptor 5-ht2c.
UA85699C2 (en) 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
WO2007028083A3 (en) 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
WO2007028132A3 (en) 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
PT1924560E (pt) 2,3,4,5-tetra-hidro-1h-benzo[d]azepinas como agonistas de receptores 5-ht2c
IL239149A (en) Inhibitors to erbb
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
GB0504828D0 (en) Therapeutic agents
WO2002036596A3 (en) CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
AU2002239463A1 (en) Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
HRP20031071A2 (en) Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
MX2008002180A (es) 2,3,4,5-tetrahidro-1h-benzo[d]azepinas 6-sustituidas como agonistas de receptor 5-ht2c.
MY124786A (en) Bis-arylsulfones
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
BG104192A (en) Substituted 4-oxo-naphthyridine-3-carboxamides as gaba brain receptor ligands
EP1581206A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH 2,3-BENZODIAZEPINES
WO2004082584A3 (en) 5ht2c receptor antagonists in the treatment of schizophrenia
EP1280781A4 (en) 5-HT7 RECEPTOR ANTAGONISTS
MXPA04003544A (es) Benzotriazepinas como ligandos del receptor de gastrina y colecistocinina.
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
AU2002256334A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino(2,3-f)quinoxaline
ATE312094T1 (de) Neue heteroarylderivate, deren herstellung und verwendung
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
DE60204882D1 (de) Zykloalkenylsulfonamidderivate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal